On December 1, 2025, Agilent Technologies Inc. (NYSE: A) announced a significant advancement in its product offerings with the release of a new 21 CFR Part 11 compliance software tailored for the xCELLigence Real-Time Cell Analysis (RTCA) eSight system. This innovative software aims to enhance the utility of the RTCA eSight in both research and regulated manufacturing environments, addressing the growing need for regulatory compliance in the biopharmaceutical sector.

2. Key Features of the New Software

The newly launched compliance software integrates a compliance license with advanced security features, thereby positioning the xCELLigence RTCA eSight as a versatile tool for drug discovery, development, and GMP-regulated manufacturing.

Enhanced Security and Compliance

The software is designed to meet stringent regulatory standards, particularly in environments where data integrity and audit-readiness are paramount. Key features include:

Secure User Authentication: Ensures that only authorized personnel can access sensitive data.

Electronic Signatures: Provides a digital method for verifying the authenticity of records.

Complete Audit Trails: Offers detailed logs of all user interactions, guaranteeing that data is trustworthy and attributable.

These enhancements assure users that their electronic records comply with regulatory standards, thereby streamlining audits and supporting successful regulatory submissions.

3. Benefits Across the Pharma Value Chain

The introduction of 21 CFR Part 11 compliance to the xCELLigence RTCA eSight system is expected to have far-reaching implications across the pharmaceutical and biopharmaceutical value chain. By extending the platform's applicability from early-stage drug discovery to production, Agilent aims to reduce variability, save time, and simplify compliance processes throughout the drug development pipeline.

Dr. Knut Wintergerst, Vice President and General Manager of the Cell and Biomolecular Analysis Division at Agilent, emphasized the importance of this development, stating, “Adding 21 CFR Part 11 compliance to the Agilent xCELLigence RTCA eSight ensures that customers can rely on their data not just for breakthrough scientific discoveries and insights, but also for regulatory compliance.” This statement underscores Agilent’s commitment to becoming a trusted partner in both scientific discovery and regulated environments.

4. Commitment to Regulatory Readiness

Agilent's latest offering reflects its dedication to providing reliable, compliance-ready solutions that support customers at every stage of developing next-generation cell therapies. By integrating compliance features directly into their existing platforms, Agilent is not only enhancing user confidence but also reinforcing its position as a leader in the analytical and clinical laboratory technologies market.

5. Conclusion

The launch of the 21 CFR Part 11 compliance software for the xCELLigence RTCA eSight system marks a pivotal moment for Agilent Technologies as it continues to innovate and adapt to the evolving needs of the biopharmaceutical industry. As the demand for regulatory-ready digital lab tools continues to rise, Agilent's enhancements ensure that their solutions remain at the forefront of technology, helping customers navigate the complexities of drug development and manufacturing.

About Agilent Technologies

Agilent Technologies, Inc. is a global leader in analytical and clinical laboratory technologies, offering a comprehensive range of instruments, software, services, and expertise to help customers tackle their most challenging questions. With a revenue of $6.95 billion in fiscal year 2025 and approximately 18,000 employees worldwide, Agilent remains committed to delivering insights and innovation that bring great science to life. For more information, visit Agilent's website or follow them on social media platforms.

Original press release